Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.57

-0.8%

Nov 3 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (1334)	5/23/2002 4:52:58 PM
From: Arthur Radley	of 1475

BioTransplant (BTRN) had news from Medimmune on Medi-507, a monoclonal in trials for autoimmune diseases. BTRN stands to get a hefty percent of gross sales as a royalty—it’s very unusual to have a percentage of gross sales. The phase 2 studies in psoriasis look promising and dosing is convenient. It may appear to be a look-alike drug when compared to Amevive, which also targets CD2 but the drugs really work differently—Medi-507 binds to a different part of the receptor, which seems to have some practical advantages. The bradycardia side effect issue appears to be totally benign and presumably of no clinical significance. The stock has been under constant pressure probably from institutional selling as well as stock sales coming out of their recent buyout of Eligix (Eligix shareholders may be unloading—and this may continue for some period). "These are comments from one biotech research firm.."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next